Market Cap 850.54M
Revenue (ttm) 780,000.00
Net Income (ttm) -97.43M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -12,491.03%
Debt to Equity Ratio 0.00
Volume 10,100
Avg Vol 28,320
Day's Range N/A - N/A
Shares Out 43.66M
Stochastic %K 48%
Beta 0.35
Analysts Strong Sell
Price Target $36.50

Company Profile

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases in Switzerland, Iceland, and internationally. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective a...

Industry: Biotechnology
Sector: Healthcare
Phone: 41-41-711-3960
Website: oculis.com
Address:
Bahnhofstrasse 20, Zug, Switzerland
JarvisFlow
JarvisFlow May. 9 at 11:00 AM
Chardan Capital updates rating for Oculis Holding ( $OCS ) to Buy, target set at 28 → 33.
0 · Reply
Armonica423
Armonica423 May. 6 at 5:55 PM
$OCS CYDY
0 · Reply
JarvisFlow
JarvisFlow Apr. 17 at 12:00 PM
Chardan Capital updates rating for Oculis Holding ( $OCS ) to Buy, target set at 28.
0 · Reply
JarvisFlow
JarvisFlow Apr. 17 at 11:00 AM
HC Wainwright & Co. has updated their rating for Oculis Holding ( $OCS ) to Buy with a price target of 32.
0 · Reply
briefingcom
briefingcom Apr. 10 at 12:15 PM
$OCS: Oculis Holding AG completed enrollment in both Phase 3 DIAMOND-1 and DIAMOND-2 trials of OCS-01 eye drops in DME, designed as pivotal registration studies to support global marketing applications including NDA submission and approval by the FDA https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20250410055909OCS&utm_campaign=inplay&utm_medium=social&utm_source=st&utm_content=view_page
0 · Reply
briefingcom
briefingcom Apr. 10 at 11:53 AM
Gapping up: $KROS +17.6% $LOVE +16.2% $SOXS +8.3% $OCS +5.6%
0 · Reply
G101SPM
G101SPM Apr. 9 at 6:47 PM
$OCS $15.85 bid. SELL/TAKE PROFIT *DAC (dollar average cost) $10.05 (11.10.23) * Click SEARCH (magnifying glass) icon on our landing page to review the postings.
0 · Reply
MomentumRanger8
MomentumRanger8 Mar. 28 at 7:27 AM
$OCS making waves in the clean energy sector. ⚡ With sustainability in focus, this could be a long-term growth play.
0 · Reply
JarvisFlow
JarvisFlow Mar. 13 at 12:30 PM
Chardan Capital has updated their rating for Oculis Holding ( $OCS ) to Buy with a price target of 28.
0 · Reply
JarvisFlow
JarvisFlow Mar. 13 at 12:30 PM
Baird has updated their rating for Oculis Holding ( $OCS ) to Outperform with a price target of 41.
0 · Reply
Latest News on OCS
Oculis Publishes Results of 2025 Annual General Meeting

Jun 5, 2025, 4:00 AM EDT - 22 days ago

Oculis Publishes Results of 2025 Annual General Meeting


Oculis to Participate in Upcoming June Investor Conferences

Jun 3, 2025, 4:00 AM EDT - 24 days ago

Oculis to Participate in Upcoming June Investor Conferences


Oculis Publishes Invitation to the Annual General Meeting

May 9, 2025, 4:05 PM EDT - 7 weeks ago

Oculis Publishes Invitation to the Annual General Meeting


Oculis to Present at Upcoming May Investor Conferences

May 7, 2025, 4:00 AM EDT - 7 weeks ago

Oculis to Present at Upcoming May Investor Conferences


Oculis Updates Share Capital

Apr 25, 2025, 4:00 PM EDT - 2 months ago

Oculis Updates Share Capital


Oculis and EURETINA Announce the 2025 Ramin Tadayoni Award

Apr 17, 2025, 5:00 AM EDT - 2 months ago

Oculis and EURETINA Announce the 2025 Ramin Tadayoni Award


Oculis to Present at Upcoming March Investor Conference

Mar 5, 2025, 4:00 AM EST - 4 months ago

Oculis to Present at Upcoming March Investor Conference


Oculis Is An Interesting Growth Bet On Non-Invasive Eye Care

Jan 21, 2025, 8:00 AM EST - 5 months ago

Oculis Is An Interesting Growth Bet On Non-Invasive Eye Care


Oculis to Present at the Stifel 2024 Healthcare Conference

Nov 13, 2024, 4:00 AM EST - 8 months ago

Oculis to Present at the Stifel 2024 Healthcare Conference


Oculis to Present at Upcoming September Investor Conferences

Aug 29, 2024, 4:00 AM EDT - 10 months ago

Oculis to Present at Upcoming September Investor Conferences


Oculis Publishes Consolidated Q2 Financial Statements and MD&A

Aug 27, 2024, 4:00 PM EDT - 10 months ago

Oculis Publishes Consolidated Q2 Financial Statements and MD&A


Oculis and EURETINA Announces the Ramin Tadayoni Award

Jun 27, 2024, 6:30 AM EDT - 1 year ago

Oculis and EURETINA Announces the Ramin Tadayoni Award


Oculis to Participate at Upcoming April Investor Conferences

Apr 4, 2024, 6:30 AM EDT - 1 year ago

Oculis to Participate at Upcoming April Investor Conferences


Oculis to Present at Upcoming February Investor Conferences

Jan 29, 2024, 6:30 AM EST - 1 year ago

Oculis to Present at Upcoming February Investor Conferences


JarvisFlow
JarvisFlow May. 9 at 11:00 AM
Chardan Capital updates rating for Oculis Holding ( $OCS ) to Buy, target set at 28 → 33.
0 · Reply
Armonica423
Armonica423 May. 6 at 5:55 PM
$OCS CYDY
0 · Reply
JarvisFlow
JarvisFlow Apr. 17 at 12:00 PM
Chardan Capital updates rating for Oculis Holding ( $OCS ) to Buy, target set at 28.
0 · Reply
JarvisFlow
JarvisFlow Apr. 17 at 11:00 AM
HC Wainwright & Co. has updated their rating for Oculis Holding ( $OCS ) to Buy with a price target of 32.
0 · Reply
briefingcom
briefingcom Apr. 10 at 12:15 PM
$OCS: Oculis Holding AG completed enrollment in both Phase 3 DIAMOND-1 and DIAMOND-2 trials of OCS-01 eye drops in DME, designed as pivotal registration studies to support global marketing applications including NDA submission and approval by the FDA https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20250410055909OCS&utm_campaign=inplay&utm_medium=social&utm_source=st&utm_content=view_page
0 · Reply
briefingcom
briefingcom Apr. 10 at 11:53 AM
Gapping up: $KROS +17.6% $LOVE +16.2% $SOXS +8.3% $OCS +5.6%
0 · Reply
G101SPM
G101SPM Apr. 9 at 6:47 PM
$OCS $15.85 bid. SELL/TAKE PROFIT *DAC (dollar average cost) $10.05 (11.10.23) * Click SEARCH (magnifying glass) icon on our landing page to review the postings.
0 · Reply
MomentumRanger8
MomentumRanger8 Mar. 28 at 7:27 AM
$OCS making waves in the clean energy sector. ⚡ With sustainability in focus, this could be a long-term growth play.
0 · Reply
JarvisFlow
JarvisFlow Mar. 13 at 12:30 PM
Chardan Capital has updated their rating for Oculis Holding ( $OCS ) to Buy with a price target of 28.
0 · Reply
JarvisFlow
JarvisFlow Mar. 13 at 12:30 PM
Baird has updated their rating for Oculis Holding ( $OCS ) to Outperform with a price target of 41.
0 · Reply
JarvisFlow
JarvisFlow Mar. 13 at 11:00 AM
HC Wainwright & Co. has adjusted their stance on Oculis Holding ( $OCS ), setting the rating to Buy with a target price of 30 → 29.
0 · Reply
G101SPM
G101SPM Mar. 5 at 8:26 PM
$OCS $18.97 bid. DAC (dollar average cost) $10.05 (11.10.23). EXIT $25.00 - Legacy Holding status. BRIEF: Today announced that Oculis will be attending and presenting at the following upcoming investor conference: Leerink Global Healthcare Conference Presenter: Sylvia Cheung, Chief Financial Officer Presentation date and time: March 11, 2025 at 3:00pm ET Location: Miami Beach, FL
0 · Reply
DonCorleone77
DonCorleone77 Feb. 18 at 12:14 PM
$OCS Oculis 5M share Secondary priced at $20.00 BofA and Leerink acted as joint book running managers for the offering.
0 · Reply
G101SPM
G101SPM Feb. 14 at 11:26 AM
$OCS $21.60 last bid. DAC $10.05 (11.10.23). EXIT $25.00. UPDATE:Oculis Holding(OCS) said late Thursday it priced an underwritten offering of 5 million ordinary shares at $20 apiece, targeting gross proceeds of $100 million. ^ The company said the "oversubscribed" offering will likely close on or about Feb. 18. The new shares will bring the total number of registered shares to more than 53.9 million before closing. ^ Oculis intends to use the net proceeds to, among other things, advance and accelerate its clinical development pipeline, particularly its neuroprotective clinical candidate Privosegtor, or OCS-05
0 · Reply
Alejanford
Alejanford Jan. 21 at 4:01 PM
$NVS $OCGN $OCS 💥 Boom 🚀 MYNZ 🔥 PR out: launches eAArly DETECT 2 to validate next-gen CRC test. Results Q4 2025, FDA re-submission next! PT $10 EOD, btw Petra’s hinted on X about FDA too, so we’re going to see more PRs this week for sure. Only way up !!! Trump ❤
0 · Reply
LawyerTradering
LawyerTradering Jan. 14 at 3:15 PM
$OCS Drifting back to $19 level after excitement over 2d phase results subsides and those who bought at $23 are left holding the bag for at least a year before new results come in.
0 · Reply
LawyerTradering
LawyerTradering Jan. 13 at 3:40 PM
$OCS to settle down to $19.50 - $20 by end of week. New trials and marketing the product are far in the future.
0 · Reply
IsabellaDC
IsabellaDC Jan. 10 at 3:49 PM
1 · Reply
Doozio
Doozio Jan. 8 at 11:33 PM
$OCS WIT them SKWD jabronis? Barring a faatch 💣. Obviously
0 · Reply
IsabellaDC
IsabellaDC Jan. 8 at 2:32 PM
Only 4 stocks on the all-time high scan: $BSX $OCS $AACT $CEPO
0 · Reply
jewell69
jewell69 Jan. 7 at 5:12 PM
$OCS I want to buy, but not on a day + 2.97%
0 · Reply
ElonMustLoveYou
ElonMustLoveYou Jan. 7 at 9:11 AM
$OCS Stifel analysts maintained their Buy rating and $35 price target for Oculis Holding AG shares.
0 · Reply